Benjamin M Ellingson1, Robert J Harris2, Davis C Woodworth2, Kevin Leu2, Okkar Zaw2, Warren P Mason2, Solmaz Sahebjam2, Lauren E Abrey2, Dana T Aftab2, Gisela M Schwab2, Colin Hessel2, Albert Lai2, Phioanh L Nghiemphu2, Whitney B Pope2, Patrick Y Wen2, Timothy F Cloughesy2. 1. UCLA Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (B.M.E., R.J.H., D.C.W., K.L., O.Z.); Dept. of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (B.M.E., R.J.H., D.C.W., K.L., O.Z., W.B.P.); Dept. of Physics and Biology in Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (B.M.E.); Dept. of Medicine, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada (W.P.M.);H. Lee Moffitt Cancer Center, Tampa, Florida (S.S.); F. Hoffman-La Roche, Ltd., Basel, Switzerland (L.E.A.); Exelixis, South San Francisco, California (D.T.A., G.M.S., C.H.); Dept. of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (A.L., P.L.N., T.F.C.); Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (P.Y.W.) bellingson@mednet.ucla.edu. 2. UCLA Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (B.M.E., R.J.H., D.C.W., K.L., O.Z.); Dept. of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (B.M.E., R.J.H., D.C.W., K.L., O.Z., W.B.P.); Dept. of Physics and Biology in Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (B.M.E.); Dept. of Medicine, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada (W.P.M.);H. Lee Moffitt Cancer Center, Tampa, Florida (S.S.); F. Hoffman-La Roche, Ltd., Basel, Switzerland (L.E.A.); Exelixis, South San Francisco, California (D.T.A., G.M.S., C.H.); Dept. of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (A.L., P.L.N., T.F.C.); Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (P.Y.W.).
Abstract
BACKGROUND: The prognostic significance of baseline contrast enhancing tumor prior to second- or third-line therapy in recurrent glioblastoma (GBM) for overall survival (OS) remains controversial, particularly in the context of repeated surgical resection and/or use of anti-angiogenic therapy. In the current study, we examined recurrent GBM patients from both single and multicenter clinical trials to test whether baseline enhancing tumor volume, including central necrosis, is a significant prognostic factor for OS in recurrent GBM. METHODS: Included were 497 patients with recurrent GBM from 4 data sources: 2 single-center sites (University of Toronto, University of California Los Angeles) and 2 phase II multicenter trials (AVF3708G, Bevacizumab ±Irinotecan, NCT00345163; XL184-201, Cabozantinib, NCT00704288). T1 subtraction maps were used to define volume of contrast enhancing tumor, including central necrosis. Cox multivariable and univariate analyses were used to evaluate the relationship between tumor volume prior to second- or third-line therapy and OS. RESULTS: Both continuous measures of baseline tumor volume and tumors dichotomized into large (≥15cc) and small (<15cc) tumors were significant predictors of OS (P<.0001), independently of age and treatment. Univariate analysis demonstrated significant OS differences (P<.05) between large (≥15cc) and small (<15cc) tumors in patients under all therapeutic scenarios. Only patients treated with cabozantinib who previously failed anti-angiogenic therapy did not show an OS dependence on baseline tumor volume. CONCLUSIONS: Baseline tumor volume is a significant prognostic factor in recurrent GBM. Clinical trial treatment arms must have a balanced distribution of tumor size, and tumor size should be considered when interpreting therapeutic efficacy.
RCT Entities:
BACKGROUND: The prognostic significance of baseline contrast enhancing tumor prior to second- or third-line therapy in recurrent glioblastoma (GBM) for overall survival (OS) remains controversial, particularly in the context of repeated surgical resection and/or use of anti-angiogenic therapy. In the current study, we examined recurrent GBM patients from both single and multicenter clinical trials to test whether baseline enhancing tumor volume, including central necrosis, is a significant prognostic factor for OS in recurrent GBM. METHODS: Included were 497 patients with recurrent GBM from 4 data sources: 2 single-center sites (University of Toronto, University of California Los Angeles) and 2 phase II multicenter trials (AVF3708G, Bevacizumab ± Irinotecan, NCT00345163; XL184-201, Cabozantinib, NCT00704288). T1 subtraction maps were used to define volume of contrast enhancing tumor, including central necrosis. Cox multivariable and univariate analyses were used to evaluate the relationship between tumor volume prior to second- or third-line therapy and OS. RESULTS: Both continuous measures of baseline tumor volume and tumors dichotomized into large (≥15cc) and small (<15cc) tumors were significant predictors of OS (P<.0001), independently of age and treatment. Univariate analysis demonstrated significant OS differences (P<.05) between large (≥15cc) and small (<15cc) tumors in patients under all therapeutic scenarios. Only patients treated with cabozantinib who previously failed anti-angiogenic therapy did not show an OS dependence on baseline tumor volume. CONCLUSIONS: Baseline tumor volume is a significant prognostic factor in recurrent GBM. Clinical trial treatment arms must have a balanced distribution of tumor size, and tumor size should be considered when interpreting therapeutic efficacy.
Authors: Ramon F Barajas; Joanna J Phillips; Rupa Parvataneni; Annette Molinaro; Emma Essock-Burns; Gabriela Bourne; Andrew T Parsa; Manish K Aghi; Michael W McDermott; Mitchel S Berger; Soonmee Cha; Susan M Chang; Sarah J Nelson Journal: Neuro Oncol Date: 2012-06-18 Impact factor: 12.300
Authors: Orin Bloch; Seunggu J Han; Soonmee Cha; Matthew Z Sun; Manish K Aghi; Michael W McDermott; Mitchel S Berger; Andrew T Parsa Journal: J Neurosurg Date: 2012-10-05 Impact factor: 5.115
Authors: B M Ellingson; S Sahebjam; H J Kim; W B Pope; R J Harris; D C Woodworth; A Lai; P L Nghiemphu; W P Mason; T F Cloughesy Journal: AJNR Am J Neuroradiol Date: 2013-10-17 Impact factor: 3.825
Authors: Benjamin M Ellingson; Eunhee Kim; Davis C Woodworth; Helga Marques; Jerrold L Boxerman; Yair Safriel; Robert C McKinstry; Felix Bokstein; Rajan Jain; T Linda Chi; A Gregory Sorensen; Mark R Gilbert; Daniel P Barboriak Journal: Int J Oncol Date: 2015-02-11 Impact factor: 5.650
Authors: Robert J Harris; Jingwen Yao; Ararat Chakhoyan; Catalina Raymond; Kevin Leu; Linda M Liau; Phioanh L Nghiemphu; Albert Lai; Noriko Salamon; Whitney B Pope; Timothy F Cloughesy; Benjamin M Ellingson Journal: Magn Reson Med Date: 2018-04-06 Impact factor: 4.668
Authors: Talia C Oughourlian; Jingwen Yao; Jacob Schlossman; Catalina Raymond; Matthew Ji; Hiroyuki Tatekawa; Noriko Salamon; Whitney B Pope; Johannes Czernin; Phioanh L Nghiemphu; Albert Lai; Timothy F Cloughesy; Benjamin M Ellingson Journal: J Neurooncol Date: 2020-01-24 Impact factor: 4.130
Authors: Kunal S Patel; Richard G Everson; Jingwen Yao; Catalina Raymond; Jodi Goldman; Jacob Schlossman; Joseph Tsung; Caleb Tan; Whitney B Pope; Matthew S Ji; Nhung T Nguyen; Albert Lai; Phioanh L Nghiemphu; Linda M Liau; Timothy F Cloughesy; Benjamin M Ellingson Journal: Neurosurgery Date: 2020-10-15 Impact factor: 4.654
Authors: Juan Jiménez-Sánchez; Álvaro Martínez-Rubio; Anton Popov; Julián Pérez-Beteta; Youness Azimzade; David Molina-García; Juan Belmonte-Beitia; Gabriel F Calvo; Víctor M Pérez-García Journal: PLoS Comput Biol Date: 2021-02-10 Impact factor: 4.475
Authors: Daniel N Cagney; Joohee Sul; Raymond Y Huang; Keith L Ligon; Patrick Y Wen; Brian M Alexander Journal: Neuro Oncol Date: 2018-08-02 Impact factor: 12.300
Authors: Benjamin M Ellingson; Dana T Aftab; Gisela M Schwab; Colin Hessel; Robert J Harris; Davis C Woodworth; Kevin Leu; Ararat Chakhoyan; Catalina Raymond; Jan Drappatz; John de Groot; Michael D Prados; David A Reardon; David Schiff; Marc Chamberlain; Tom Mikkelsen; Annick Desjardins; Jaymes Holland; Jerry Ping; Ron Weitzman; Patrick Y Wen; Timothy F Cloughesy Journal: Neuro Oncol Date: 2018-09-03 Impact factor: 12.300